AstraZeneca PLC is 139.2x more valuable than Immunome Inc. by market capitalization ($286.27 B vs $2.06 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | IMNM | AZN |
|---|---|---|
| Market cap | $2.06 B | $286.27 B |
| US-listed rank | #2083 | #45 |
| Revenue (latest FY) | $6.94M | - |
| Net income (latest FY) | -$212.39M | - |
| Net margin | -3060.0% | - |
| SEC filings | 416 | 1,004 |
AstraZeneca PLC is 139.2x more valuable than Immunome Inc. by market capitalization ($286.27 B vs $2.06 B).
Full pages: Immunome Inc. and AstraZeneca PLC, or browse the full rankings.